Uptake and economic impact of first-cycle colony-stimulating factor use during adjuvant treatment of breast cancer

Journal of Clinical Oncology

Volumn 30, Issue 8, 2012, Pages 806-812

  Hershman, Dawn L ^a   Wilde, Elizabeth T ^a   Wright, Jason D ^a   Buono, Donna L ^a   Kalinsky, Kevin ^a   Malin, Jennifer L ^b   Neugut, Alfred I ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE;

ADJUVANT THERAPY; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CLINICAL PRACTICE; COHORT ANALYSIS; DISEASE FREE SURVIVAL; DRUG APPROVAL; DRUG COST; DRUG DOSAGE FORM COMPARISON; FEBRILE NEUTROPENIA; FEMALE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; MULTIVARIATE ANALYSIS; ONCOLOGY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; SOCIAL STATUS; SOCIOECONOMICS; TREATMENT OUTCOME; WOMEN'S HEALTH;

AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COLONY-STIMULATING FACTORS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; NEOPLASMS, HORMONE-DEPENDENT; RECOMBINANT PROTEINS; SEER PROGRAM; SOCIOECONOMIC FACTORS; UNITED STATES;

EID: 84858843113     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.7499     Document Type: Article

References (30)

1. Citron ML, Berry DA, Cirrincione C, et al: Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-1439, 2003 (Pubitemid 46594092)
2. Venturini M, Del Mastro L, Aitini E, et al: Dose-dense adjuvant chemotherapy in early breast cancer patients: Results from a randomized trial. J Natl Cancer Inst 97:1724-1733, 2005
3. Baldini E, Gardin G, Giannessi PG, et al: Accelerated versus standard cyclophosphamide, epirubicin and 5-fluorouracil or cyclophosphamide, methotrexate and 5-fluorouracil: A randomized phase III trial in locally advanced breast cancer. Ann Oncol 14:227-232, 2003 (Pubitemid 36305434)
4. Bonilla L, Ben-Aharon I, Vidal L, et al: Dose-dense chemotherapy in nonmetastatic breast cancer: A systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst 102:1845-1854, 2010
5. Berry DA, Cirrincione C, Henderson IC, et al: Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658-1667, 2006
6. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
7. Vose JM, Crump M, Lazarus H, et al: Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 21:514-519, 2003 (Pubitemid 46606482)
8. Holmes FA, O'Shaughnessy JA, Vukelja S, et al: Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 20:727-731, 2002 (Pubitemid 34111380)
9. Green MD, Koelbl H, Baselga J, et al: A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14:29-35, 2003 (Pubitemid 36150255)
10. Aapro MS, Cameron DA, Pettengell R, et al: EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42:2433-2453, 2006 (Pubitemid 44442936)
11. Smith TJ, Khatcheressian J, Lyman GH, et al: 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 24:3187-3205, 2006 (Pubitemid 46638957)
12. Potosky AL, Malin JL, Kim B, et al: Use of colony-stimulating factors with chemotherapy: Opportunities for cost savings and improved outcomes. J Natl Cancer Inst 103:979-982, 2011
13. Liu Z, Doan QV, Malin J, et al: The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK. Appl Health Econ Health Policy 7:193-205, 2009
14. Potosky AL, Riley GF, Lubitz JD, et al: Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care 31:732-748, 1993
15. Du XL, Fang S, Vernon SW, et al: Racial disparities and socioeconomic status in association with survival in a large population-based cohort of elderly patients with colon cancer. Cancer 110:660-669, 2007 (Pubitemid 47106157)
16. Charlson ME, Sax FL, MacKenzie CR, et al: Assessing illness severity: Does clinical judgment work? J Chronic Dis 39:439-452, 1986 (Pubitemid 16044157)
17. Klabunde CN, Potosky AL, Legler JM, et al: Development of a comorbidity index using physician claims data. J Clin Epidemiol 53:1258-1267, 2000 (Pubitemid 32007842)
18. Hershman DL, Buono D, Jacobson JS, et al: Surgeon characteristics and use of breast conservation surgery in women with early stage breast cancer. Ann Surg 249:828-833, 2009
19. Hershman DL, Buono D, McBride RB, et al: Influence of private practice setting and physician characteristics on the use of breast cancer adjuvant chemotherapy for elderly women. Cancer 115:3848-3857, 2009
20. Hershman DL, Buono D, McBride RB, et al: Surgeon characteristics and receipt of adjuvant radiotherapy in women with breast cancer. J Natl Cancer Inst 100:199-206, 2008 (Pubitemid 351480552)
21. Vanchieri C: When will the U.S. flinch at cancer drug prices? J Natl Cancer Inst 97:624-626, 2005
22. Benson R, Wilson C, Williams MV: Comments on Costs of treating advanced colorectal cancer, Ross et al., Eur J Cancer 1996, 32A, S13-S17. Eur J Cancer 34:593-594, 1998 (Pubitemid 128716710)
23. U.S. Department of Health and Human Services: Office of Inspector General Report. http://oig.hhs.gov/oei/reports/oei-03-09-00510.pdf, 2011
24. Doloresco F, Fominaya C, Schumock GT, et al: Projecting future drug expenditures: 2011. Am J Health Syst Pharm 68:921-932, 2011
25. Smith RE: Risk for the development of treatment-related acute myelocytic leukemia and myelodysplastic syndrome among patients with breast cancer: Review of the literature and the National Surgical Adjuvant Breast and Bowel Project experience. Clin Breast Cancer 4:273-279, 2003
26. Relling MV, Boyett JM, Blanco JG, et al: Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 101:3862-3867, 2003 (Pubitemid 36857858)
27. Hershman D, Neugut AI, Jacobson JS, et al: Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 99:196-205, 2007
28. Lyman GH, Dale DC, Wolff DA, et al: Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: A systematic review. J Clin Oncol 28:2914-2924, 2010
29. Griggs JJ, Culakova E, Sorbero ME, et al: Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol 25:2522-2527, 2007 (Pubitemid 47041224)
30. Hershman DL, Wang X, McBride R, et al: Delay in initiating adjuvant radiotherapy following breast conservation surgery and its impact on survival. Int J Radiat Oncol Biol Phys 65:1353-1360, 2006 (Pubitemid 44425226)